PrEP works if you take it. The figures on this graphic show the relationship between PrEP efficacy and adherence and the status of regulatory action on PrEP worldwide. It also shows other potential new formulations of ARV-based prevention being evaluated as additional options in the future.
PrEP by the Numbers: Efficacy, regulatory approval and more
The Tipping Point: Moving From Rhetoric to Real Milestones for Ending AIDS
One way to measure progress in fighting AIDS is to compare the number of new HIV infections with the increase in HIV positive people on antiretroviral therapy (ART) over a given time period. An AIDS epidemic reaches its “tipping point” when the number of annual new HIV infection falls below the annual increase in patients starting ART. This poster was presented at the 2014 HIV Research for Prevention Conference in South Africa.
Resource Tracking to Ensure Accountability and Sustainability: HIV Prevention, Treatment U=U, Diagnostics and Cure Research Investment Analysis
This infographic explains how AVAC tracks HIV expenditures and investments. This has resulted in accurate and consistent year-to-year comparisons of grants and investment figures. This poster was presented at the 2014 HIV Research for Prevention (R4P) conference in South Africa.
Progress in VMMC Scale-up in Priority Countries
This map shows progress made through 2013 towards the target of circumcising 80% of eligible men in 14 priority countries. It is particularly useful as a tool for advocates to show how their country’s VMMC program compares to others in East and Southern Africa.
Global Investment in HIV Cure Research and Development in 2013
The International AIDS Society HIV Cure Resource Tracking group joined with the HIV Vaccines and Microbicides Tracking Working Group to estimate global investments in HIV cure research and produce this short report.
HIV Prevention Research & Development Investment in 2013: In a changing global development, economic and human rights landscape
This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. The report shows that investment in HIV prevention research fell 4 percent in 2013, due to a combination of factors including declining investments by the United States and European donors, changes in the international development landscape and changes in the pipeline of HIV prevention products being tested.
When do you stop an HIV prevention trial for futility? A primer for HIV prevention advocates
This fact sheet looks at why trials are stopped early for “futility.” What does this mean, when is such a recommendation made and how does it affect other ongoing trials?
Jeff McConnell Memorial Webinar – Audio
This webinar memorialized pioneering sociologist Jeff McConnell and his impact on HIV prevention science. Updates were presented on pre-exposure prophylaxis (PrEP) research and the implications of Dr. McConnell’s research on sexual networks for how PrEP will be implemented.Find details, slides and full flash webinar here.
HIV Prevention Europe Webinars: Rectal microbicides
The seventh webinar in our series addressing a range of topics in HIV prevention research, hosted jointly by NAM and AVAC, focused on rectal microbicides. Speakers included: Ian McGowan, University of Pittsburgh; Carolina Herrera, Imperial College; Alex Carballo-Dieguez, Columbia University; and Marc-André LeBlanc, IRMA.
The presentation was followed by a Q&A session. Click here for slides and audio from the webinar.
Will a pill a day prevent HIV? Anticipating the results of the tenofovir “PrEP” trials
This 2005 report examines the issues surrounding the tenofovir trials and makes recommendations for ensuring that trials are carried out ethically and that provisions are made for dealing with the results of the trials when they are available. The report also calls for more concerted coordination and advance planning to accelerate evaluation, licensing, and access to PrEP.